BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS^™ in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. announced initiation of a first-in-human, Phase I/II study evaluating safety and efficacy of Bria-OTS™, BriaCell’s personalized off-the-shelf next generation immunotherapy, as monotherapy and in combination with PD-1 inhibitor tislelizumab, in advanced metastatic breast cancer.